Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral: Vanier Canada Graduate Scholarships

University of Calgary

$150,000.00

Risk of chronic kidney disease progression and the impact of current therapies in children with immunoglobulin A nephropathy

FY 2022-23

Summary
Immunoglobulin A or IgA nephropathy is a kidney disease of unknown cause where the filtering units of the kidney are damaged resulting in blood and protein leaking into the urine. Forty percent of persons with IgA nephropathy will have kidney failure requiring dialysis and kidney transplants in the future. Treating children with IgA nephropathy is particularly challenging. There is no specific treatment, and we don't know which of the available treatments work best. Current treatments include supportive drugs to reduce protein in the urine, and immunosuppressive drugs. Many of the immunosuppressive drugs, such as steroids, have significant side effects in children, and their benefits in this disease are unclear. Therefore, the goals of our research are: 1. To summarize what is known about the effectiveness of treatments for IgA nephropathy in children through a systematic review of the medical literature. 2. We will then identify children with IgA nephropathy in Alberta using a special kidney biopsy registry and follow them forward in time to understand what happens to their kidney function. We will determine risk factors for kidney failure and examine if treatment with immunosuppressive drugs reduces kidney failure. 3. Finally, we will develop a local clinical guideline for the treatment of IgA nephropathy in children in Alberta. We will form a working group composed of health professionals and patients in Alberta and use specific tools designed for guideline development. This project will advance our understanding of IgA nephropathy in children and help us to improve the way we treat these children. It will provide information on IgA nephropathy in children in Canada and will help us to design future studies to find a cure.
Program
Doctoral: Vanier Canada Graduate Scholarships
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
474567
Name
Alladin-Karan Bibi A
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Human Development, Child and Youth Health
Theme2
Clinical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Risk of chronic kidney disease progression and the impact of current therapies in children with immunoglobulin A nephropathy
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Children; Cohort Study; Glomerulonephritis; Immunoglobulin A Nephropathy; Kidney Disease; Knowledge Translation; Pediatrics; Steroids; Systematic Reviews; Treatment
Abstract
Immunoglobulin A or IgA nephropathy is a kidney disease of unknown cause where the filtering units of the kidney are damaged resulting in blood and protein leaking into the urine. Forty percent of persons with IgA nephropathy will have kidney failure requiring dialysis and kidney transplants in the future. Treating children with IgA nephropathy is particularly challenging. There is no specific treatment, and we don't know which of the available treatments work best. Current treatments include supportive drugs to reduce protein in the urine, and immunosuppressive drugs. Many of the immunosuppressive drugs, such as steroids, have significant side effects in children, and their benefits in this disease are unclear. Therefore, the goals of our research are: 1. To summarize what is known about the effectiveness of treatments for IgA nephropathy in children through a systematic review of the medical literature. 2. We will then identify children with IgA nephropathy in Alberta using a special kidney biopsy registry and follow them forward in time to understand what happens to their kidney function. We will determine risk factors for kidney failure and examine if treatment with immunosuppressive drugs reduces kidney failure. 3. Finally, we will develop a local clinical guideline for the treatment of IgA nephropathy in children in Alberta. We will form a working group composed of health professionals and patients in Alberta and use specific tools designed for guideline development. This project will advance our understanding of IgA nephropathy in children and help us to improve the way we treat these children. It will provide information on IgA nephropathy in children in Canada and will help us to design future studies to find a cure.
Competitiondate
202211
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Alladin-Karan, Bibi A
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~
University of Calgary - $150,000 Grant (2022-23) | Canada Spends